• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

    7/17/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email
    • Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders
    • The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250717183186/en/

    The 2025 Dexcom U roster consists of 21 athletes, with 13 new and eight returning team members, who all use Dexcom CGM to monitor their glucose levels and manage their diabetes.

    The 2025 Dexcom U roster consists of 21 athletes, with 13 new and eight returning team members, who all use Dexcom CGM to monitor their glucose levels and manage their diabetes.

    This year's Dexcom U roster welcomes 13 new athletes from colleges and universities across the country — including the University of Oregon, San Diego State University, and Northwestern University — representing 12 sports such as football, basketball, lacrosse, track & field, soccer, and more, alongside eight returning team members. The new athletes were selected following a dynamic, first-of-its-kind nationwide open call that drew over two hundred submissions, as Dexcom searched for the next great college athletes with diabetes to join the program.

    To officially welcome and celebrate the newly selected Dexcom U athletes, Dexcom hosted its Signing Day Camp earlier this month in Baltimore, Maryland. The event was hosted by Mark Andrews, Baltimore Ravens tight end and Dexcom Warrior, who relies on Dexcom G7 to manage his Type 1 diabetes and perform at the highest level. Mark was joined by Mike Golic Sr., NFL legend and sports broadcaster, who uses Stelo, Dexcom's over the counter glucose biosensor, to manage his Type 2 diabetes. The powerful, high-energy day brought together athletes with diabetes across all levels, including pro, college and youth sports, to redefine what's possible with diabetes. Both new and returning Dexcom U team members connected with Baltimore youth athletes and celebrated the resilience and determination that unite them.

    "It was incredibly inspiring to witness athletes of all ages come together at the Dexcom U Signing Day Camp to show what is possible while living with diabetes," said Mark Andrews, Dexcom Warrior and Baltimore Ravens tight end. "I know how impactful it would have been to have a support system like this in the early stages of my career, so for me, getting to be the role model I never had is really special."

    Dexcom U was created to elevate college athletes with diabetes who are breaking boundaries in sports and achieving their goals, despite their diagnosis. Since its inception in 2022, the program has directly impacted more than 40 college athletes across 38 schools and 19 sports. Each Dexcom U athlete relies on Dexcom continuous glucose monitoring (CGM) technology like Dexcom G7 to manage their diabetes with real-time data delivered directly to their smartphone or smartwatch,* empowering them to take control of their health and discover what they're made of.

    "This season, we set out to grow Dexcom U in ways that bring even more athletes into our Warrior community. From launching a new nationwide Open Call to hosting our first Dexcom U Signing Day Camp, we're creating impactful opportunities for athletes with diabetes to shine," said Leverne Marsh, executive vice president of marketing at Dexcom. "It's all part of our mission to show how Dexcom's continuous glucose monitoring technology supports performance, confidence, and connection."

    The 2025 Dexcom U roster consists of 21 athletes, with 13 new and eight returning team members, who all use Dexcom CGM to monitor their glucose levels and manage their diabetes:

    New athletes:

    • Ali Ramadan, Soccer, Creighton University
    • Anya Tribune, Soccer, Gardner-Webb University
    • Ari Long, Basketball, University of Oregon
    • Breanna Corral-Vargas, Acrobatics & Tumbling, Hawaii Pacific University
    • Clarke Byram, Track & Field, Pole Vault, University of Tennessee, Knoxville
    • Jackson Montgomery, Baseball, Coppin State University
    • Kya Epps, Track & Field, University of Cincinnati
    • Michael Trepeta, Lacrosse, Johns Hopkins University
    • Miles Byrd, Basketball, San Diego State University
    • Nadia Nemeth, Field Hockey, Northwestern University
    • Niamh Pfaff, Lacrosse, Yale University
    • Nikola Parichkov, Tennis, Wake Forest University
    • Patrick Heneghan, Football, Denison University

    Returning athletes:

    • Ben Mirisch, Water Polo, University of Southern California
    • Caleb Fauria, Football, University of Delaware
    • Isaac Traudt, Basketball, Creighton University
    • Jessica Walter, Softball, University of Connecticut
    • Madison Moraja, Track & Field, North Carolina State University
    • Nicholas Hahne, Cheerleading, University of Notre Dame
    • Raegan Lantz, Volleyball, Miami (OH) University
    • Shelomi Sanders, Basketball, Alabama A&M University

    Dexcom U athletes will receive access to Dexcom CGM, exclusive events and opportunities, and a supportive network of collegiate and professional athletes — including mentors like Seattle Sounders forward Jordan Morris and Dexcom U alum and Vegas Thrill setter Carly Graham — who support one another both on and off the field.

    To learn more about Dexcom U, visit www.Dexcom.com/DexcomU2025.

    About Dexcom

    Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

    Dexcom. Discover what you're made of. For more information, visit www.dexcom.com.

    *Smart device sold separately. For a list of compatible devices, visit www.Dexcom.com/compatibility.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250717183186/en/

    Media Contact

    Aly Brandt

    [email protected]

    Investor Contact

    Sean Christensen

    [email protected]

    Get the next $DXCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    12/2/2025$75.00Equal-Weight → Overweight
    Morgan Stanley
    11/25/2025$68.00In-line
    Evercore ISI
    10/21/2025$85.00Buy
    Stifel
    9/8/2025Outperform → Perform
    Oppenheimer
    8/21/2025$100.00Buy
    Argus
    6/16/2025$102.00Buy
    Truist
    5/30/2025$104.00Buy
    Goldman
    4/10/2025$85.00Outperform
    Mizuho
    More analyst ratings

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dexcom upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Dexcom from Equal-Weight to Overweight and set a new price target of $75.00

    12/2/25 8:17:55 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on Dexcom with a new price target

    Evercore ISI initiated coverage of Dexcom with a rating of In-line and set a new price target of $68.00

    11/25/25 8:40:45 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Stifel resumed coverage on Dexcom with a new price target

    Stifel resumed coverage of Dexcom with a rating of Buy and set a new price target of $85.00

    10/21/25 7:19:41 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Collins Richard Alexander sold $171,599 worth of shares (2,906 units at $59.05) (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/17/25 5:52:36 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Director Heller Bridgette P sold $58,767 worth of shares (1,012 units at $58.07), decreasing direct ownership by 4% to 27,031 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/12/25 5:14:37 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    SEC Filings

    View All

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $DXCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 144 filed by DexCom Inc.

    144 - DEXCOM INC (0001093557) (Subject)

    11/12/25 10:52:52 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by DexCom Inc.

    144 - DEXCOM INC (0001093557) (Subject)

    11/10/25 9:52:13 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by DexCom Inc.

    10-Q - DEXCOM INC (0001093557) (Filer)

    10/30/25 5:19:54 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy

    New personalised learning platform aims to build confidence in healthcare professional (HCP) CGM knowledge, no matter their previous experience, and support high-quality diabetes care. Designed with HCPs for HCPs. Available as a mobile app to fit with busy HCP schedules. Now available in five countries with further expansion planned across Europe, the Middle East, and Africa (EMEA). DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of Dexcom Academy, a new personalised learning platform created with healthcare professionals (HCPs) and for healthcare professionals. The platform is now ava

    12/4/25 8:02:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States

    Designed to provide real-time glucose readings for an industry-leading 15.5 days*†, Dexcom G7 15 Day will be available in the U.S. for people over the age of 18 with diabetes beginning on Dec. 1, 2025. Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers with full retail launch in the coming weeks. Dexcom CGM continues to be the most covered and reimbursed CGM brand on the market1. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7

    11/20/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes

    Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers.* Dexcom Smart Basal is FDA cleared and now the first and only CGM-integrated basal insulin dosing optimizer for adults aged 18 and older with Type 2 diabetes who are using long-acting insulin.1 DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.1 Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged

    11/19/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Leadership Updates

    Live Leadership Updates

    View All

    Dexcom Appoints Euan Ashley to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-directo

    10/27/25 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Synchron Expands Executive Team with Appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D

    Medical device leaders who have built and scaled category-defining products join Synchron to help drive its next-generation brain-computer interface platform as well as accelerate towards commercialization Synchron, a category-defining brain-computer interface (BCI) company, today announced the appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D. The appointments bring deep experience in launching and scaling category-leading medical devices, positioning Synchron to advance its Stentrode® BCI through U.S. clinical trials and prepare for global market entry. Mr. Rasdal, who joined Synchron's Board of Directors in 2023, will transition into a full-time executive role

    8/19/25 8:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

    Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This pr

    7/17/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Financials

    Live finance-specific insights

    View All

    Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue grew 22% year-over-year to $1.209 billion on a reported basis and 20% year-over-year on an organic1 basis. U.S. revenue grew 21% and international revenue grew 22% on a reported basis and 18% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $242.5 million or 20.1% of revenue, an increase of 480 basis points compared to the third quarter of 2024. Non-GAAP operating income* of $272.9 million or 22.6% of reported revenue, an increase of 130 basis points compared to the third quarter of 2024.

    10/30/25 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.

    DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2025 financial results after market close on Thursday, October 30, 2025. Management will hold a conference call to review the company's third quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the

    10/2/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights: Revenue grew 15% year-over-year to $1.157 billion on a reported basis and 15% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 16% on a reported basis and 14% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $212.6 million or 18.4% of revenue, an increase of 270 basis points compared to the second quarter of 2024. Non-GAAP operating income* of $221.8 million or 19.2% of reported revenue, a decrease of 30 basis points compared to the second quarter of 2024. S

    7/30/25 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/13/24 5:02:33 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/23 11:16:37 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/22 3:43:37 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care